Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity - Lampson, Benjamin L.; Kasar, Siddha N.; Matos, Tiago R.; Morgan, Elizabeth A.; Rassenti, Laura; Davids, Matthew S.; Fisher, David C.; Freedman, Arnold S.; Jacobson, Caron A.; Armand, Philippe; Abramson, Jeremy S.; Arnason, Jon E.; et al. (Blood, 2016)
Keywords: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Chemical and Drug Induced Liver Injury - blood; Chemical and Drug Induced Liver Injury - genetics; Chemical and Drug Induced Liver Injury - immunology; Clinical Trials and Observations; Female; Hepatitis, Autoimmune - blood; Hepatitis, Autoimmune - genetics; Hepatitis, Autoimmune - immunology; Humans; Immunoglobulin Heavy Chains - blood; Immunoglobulin Heavy Chains - genetics; Immunoglobulin Heavy Chains - immunology; Leukemia, Lymphocytic, Chronic, B-Cell - blood; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Liver - immunology; Liver - metabolism; Liver - pathology; Male; Middle Aged; Mutation; Purines - administration & dosage; Purines - adverse effects; Quinazolinones - administration & dosage; Quinazolinones - adverse effects